Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51.

Trial Profile

Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs IC 51 (Primary)
  • Indications Japanese encephalitis
  • Focus Pharmacodynamics
  • Sponsors Intercell USA; Valneva USA
  • Most Recent Events

    • 11 Dec 2017 According to a Valneva media release, Intercell USA changed its name to Valneva USA.
    • 06 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top